Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)

Inclusion Criteria:

• Age older than 18 yearsAge older than 18 years
• Signed informed consent form
• Stable angina pectoris (CCS I-III FC) with signs of myocardial ischemia despitetreatment with antianginal drug(s) present either clinically and/ or at stress ECHOtest with dobutamine
• History of myocardial infraction occurred 6 months and more from the inclusion date
• Trimetazidine (TMZ) is recommended as add on to the current antianginal treatment andthis recommendation precedes inclusion of a patient in the study
• Intention to perform a stress echo with spackle tracking precedes the start of TMZ
• Physician's intention to perform a stress ECHO test within a 6-month period after thedate of inclusion in the study

Exclusion Criteria:

• Age over 75 years or under 18 years old
• Hypersensitivity to the active substance or any excipient specified in SmPc of TMZ 80mg OD
• Parkinson's disease, parkinsonism symptoms, tremors, restless legs syndrome and otheraccompanying movement disorders
• Known severe or moderate renal impairment (creatinine clearance <60 ml / min).
• Angina pectoris of IV functional CCS class
• Heart failure IV functional class by NYHA
• Cardiac valves insufficiency with regurgitation of stage III and higher
• Myocardial infarction less than 6 months from the inclusion date
• Acute cerebrovascular event (stroke of various origins, transient ischemic attack)within 6 months before screening date
• Uncontrolled arterial hypertension of stage 3 (blood pressure above 180/100 mm Hg)despite ongoing antihypertensive therapy
• Fructose / sucrose intolerance, presence of glucose-galactose malabsorption syndrome,sucrose-somaltase deficiency and other enzymopathies associated with intolerance tosucrose, which is part of the drug
• Pregnancy, breastfeeding
• Any contraindications to stress echocardiography with dobutamine